Literature DB >> 8274173

Assessment of MRI criteria for a diagnosis of MS.

H Offenbacher1, F Fazekas, R Schmidt, W Freidl, E Flooh, F Payer, H Lechner.   

Abstract

To test the reliability of four previously proposed MRI criteria for the diagnosis of MS, we reviewed 1,500 consecutive brain scans for the presence, number, size, and location of areas of increased signal (AIS) on proton-density and T2-weighted images, unaware of the patients' clinical presentations and ages. This series included 134 subjects with a clinical diagnosis of MS. Relying exclusively on the presence of at least three or four AIS for a positive diagnosis of MS resulted in high sensitivity (90% for three AIS and 87% for four) but inadequate specificity (71% for three AIS and 74% for four) and positive predictive value (23% for three AIS and 25% for four). If one of these lesions was required to border the lateral ventricles, specificity was 92% and positive predictive value was 50% at a sensitivity of 87%. Using the Fazekas criteria (at least three AIS and two of the following features: abutting body of lateral ventricles, infratentorial lesion location, and size > 5 mm) led to a further highly significant improvement of specificity (96%; p = 0.0000) and increase of the positive predictive value (65%) at the expense of a less significant decrease in sensitivity (81%; p < 0.01).

Entities:  

Mesh:

Year:  1993        PMID: 8274173     DOI: 10.1212/wnl.43.5.905

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis.

Authors:  M Tintoré; A Rovira; M J Martínez; J Rio; P Díaz-Villoslada; L Brieva; C Borrás; E Grivé; J Capellades; X Montalban
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

Review 2.  MR imaging of midbrain pathologies.

Authors:  E Hattingen; S Blasel; M Nichtweiss; F E Zanella; S Weidauer
Journal:  Clin Neuroradiol       Date:  2010-06-09       Impact factor: 3.649

Review 3.  Tumefactive demyelinating lesions.

Authors:  A P Dagher; J Smirniotopoulos
Journal:  Neuroradiology       Date:  1996-08       Impact factor: 2.804

4.  British Isles survey of multiple sclerosis in twins: MRI.

Authors:  J W Thorpe; C J Mumford; D A Compston; B E Kendall; D G MacManus; W I McDonald; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

5.  Patients with clinically definite multiple sclerosis, white matter abnormalities on MRI, and normal CSF: if not multiple sclerosis, what is it?

Authors:  C Fieschi; C Gasperini; G Ristori; S Bastianello; F Girmenia; V Leuzzi; C Buttinelli; M Rasura
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

6.  How do physicians respond to patient's requests for costly, unindicated services?

Authors:  T H Gallagher; B Lo; M Chesney; K Christensen
Journal:  J Gen Intern Med       Date:  1997-11       Impact factor: 5.128

7.  Neuroradiological evaluation of demyelinating disease.

Authors:  Jan-Mendelt Tillema; Istvan Pirko
Journal:  Ther Adv Neurol Disord       Date:  2013-07       Impact factor: 6.570

8.  Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H-magnetic resonance spectroscopy.

Authors:  P Kapeller; S Ropele; C Enzinger; T Lahousen; S Strasser-Fuchs; R Schmidt; F Fazekas
Journal:  J Neurol       Date:  2005-05-20       Impact factor: 4.849

9.  Reproducibility of three whole-brain N-acetylaspartate decline cohorts in relapsing-remitting multiple sclerosis.

Authors:  O Gonen; T A Oberndorfer; M Inglese; J S Babb; J Herbert; R I Grossman
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

10.  Diagnostic value of paraclinical tests in multiple sclerosis: relative sensitivities and specificities for reclassification according to the Poser committee criteria.

Authors:  S Beer; K M Rösler; C W Hess
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.